Aref Al-Kali MD

PubMed

• Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial.
  James M Foran, Zhuoxin Sun, Selina M Luger, David F Claxton, Hillard M Lazarus
  Blood Neoplasia. 2026-05-01
• Treatment-specific prognostic performance of ELN 2022, ELN 2024, and Beat AML 2024: a real-world AML validation study.
  Tariq Kewan, Oudai Alkabbani, Hadil Zureigat, Rong He, Dragan Jevremovic
  Blood Neoplasia. 2026-05-01
• CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective compari...
  Saubia Fathima, Lior Rokach, Nour Ghosoun, Mahsa Rezasoltani, Rimal Ilyas
  Blood Cancer Journal. 2026-04-06

Journal Articles

• Monosomal Karyotype Predicts Adverse Prognosis in Patients Diagnosed with Chronic Myelomonocytic Leukemia (CMML): A Single Institution Experience  
  A Alsahlawi, H Alkhateeb, M Patnaik, K Begna, M Elliott, W Hogan, M Litzow, A Al-Kali, Clinical Lymphoma, Myeloma and Leukemia, 6/10/2014
• Toxoplasmosis in Patients with hematologic Malignancies  
  A Chintakuntlawar, M Kidd, A Al-Kali, W Wilson, CA Thompson, Leuk Lymphoma, 5/31/2014
• Revised Assessment of Response and Long-term Discontinuation Rates among 111 Patients with Myelofibrosis Treated with Momelotinib and Ruxolitinib  
  Abdelrahman RA, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, Tefferi A, Leukemia, 1/1/2014

Books/Book Chapters

• Chronic Myeloid Leukemia: From Daily Management to Complicated Issues 
  Chapter: Chapter IX: Management of Chornic Myeloid Leukemia (CML): Accelerated Phase (AP) 
  Nova Science Publishers2014
• Chronic Myeloid Leukemia: From Daily Management to Complicated Issues 
  Chapter: Chapter X: Management of Chornic Myeloid Leukemia (CML): Blast Phase (BP) 
  Nova Science Publishers2014

Abstracts/Posters

• Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ...
  Aref Al-Kali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• DNA Cytosine-Demethylating Agent 5-Aza-2'-Deoxycytidine Targets Leukemia Cells through Reducing DNA N6-Methyladenine
  Aref Al-Kali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic...
  Aref Al-Kali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

• A phase II study (NCI9775) of sapanisertib (MLN0128/TAK-228) in relapsed and/or refractory acute lymphoblastic leukemia (ALL): Interim analysis. 
  2019 ASCO Annual Meeting - 6/1/2019
• A Phase II of Combination Daunorubicin and Cytarabine (Ara-c) and Nilotinib (TAsigna) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Hematological Emergencies in the ICU 
  8/19/2014